

DEXCOM INC  
Form 8-K  
March 07, 2007

## UNITED STATES

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **March 7, 2007**

### DexCom, Inc.

(Exact Name of the Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

**000-51222**

(Commission  
File Number)

**33-0857544**

(IRS Employer  
Identification No.)

**5555 Oberlin Drive, San Diego, CA**

(Address of Principal Executive Offices)

**92121**

(Zip Code)

**(858) 200-0200**

(Registrant's Telephone Number, Including Area Code)

**(Former Name or Former Address, If Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01: Other Events.**

On March 7, 2007 DexCom, Inc. (the Company ) issued a press release announcing the pricing of an additional \$20 million aggregate principal amount of 4.75% Convertible Senior Notes due 2027 (the Additional Notes ) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. On March 6, 2007, the Company issued a press release announcing the pricing of \$40 million aggregate principal amount of Convertible Senior Notes due 2027 (the Notes ). The Company intends to use a portion of the net proceeds from the sale of the Additional Notes to enter into call spread transactions on its common stock that relate to the entire amount of Notes and Additional Notes that the Company issues in order to reduce the potential dilution from conversion of the Notes and Additional Notes. Attached as Exhibit 99.1 is the press release of the Company regarding the pricing of its offering the Additional Notes. Exhibit 99.1 is incorporated by reference under this Item 8.01.

**Item 9.01: Financial Statements and Exhibits.**

(d) Exhibits.

| <u>Number</u> | <u>Description</u> |
|---------------|--------------------|
|---------------|--------------------|

|       |   |
|-------|---|
| 99.01 | Press release dated March 7, 2007 regarding the pricing of an additional \$20 million of 4.75% Convertible Senior Notes due 2027. |
|-------|---|

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DEXCOM, INC.

By: */s/ Steven J. Kemper*  
Steven J. Kemper  
Chief Financial Officer

Date: March 7, 2007

---

**Exhibit Index**

| <u>Number</u> | <u>Description</u>  | - |
|---------------|---|---|
| 99.01         | Press release dated March 7, 2007 regarding the pricing of an additional \$20 million of 4.75% Convertible Senior Notes due 2027. |   |

---